Ivacaftor in French Patients With Cystic Fibrosis and a G551D Mutation - Efficacy and Safety Results After the First Year of Treatment in the Real Life Setting.
Phase of Trial: Phase IV
Latest Information Update: 04 Aug 2016
At a glance
- Drugs Ivacaftor (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- Acronyms IVACAFTOR1
- 31 Jul 2016 Status changed from active, no longer recruiting to completed.
- 15 Dec 2015 Planned number of patients changed from 58 to 57 as per ClinicalTrials.gov record.
- 15 Dec 2015 Planned End Date changed from 1 Nov 2015 to 1 Nov 2016 as per ClinicalTrials.gov record.